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Abstract 
The synovium is the major target tissue of inflammatory arthritides such as rheumatoid 
arthritis (RA). The study of synovial tissue has advanced significantly over a number of 
decades from arthroplasty, blind needle biopsy and more recently facilitated by arthroscopic 
and ultrasonographic technology that allows easier visualisation and improves the reliability 
of obtaining synovial biopsies. The potential for study of pathogenesis, patient stratification, 
discovery of biomarkers and novel targets, as well as validation of therapy, have all been 
progressed rapidly in the last decade, facilitated by increasingly diverse and sophisticated 
analytical and technological approaches. In this review we describe clinical and translational 
developments in the field of synovial tissue research, outlining current and novel investigative 
technologies, and highlight their application to advance our understanding of the aforegoing 
imperatives. 
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Introduction 
 
1.1 General Considerations 
 
Chronic inflammatory arthritides (IA) comprise a heterogeneous group of diseases 
characterised by inflammation of the synovium, often accompanied by destruction of 
adjacent cartilage and bone. Inflammation is characterised by synovial neovascularisation, 
stromal proliferation and leukocyte extravasation.1 For the purpose of this review we will 
focus on rheumatoid arthritis (RA), due to its prevalence, and there being the most extensive 
body of research on this common cause of synovitis. RA is usually persistent and progressive, 
leading to joint damage, disability and deformity if left untreated. RA is associated with a 
reduction in quality of life as well as decreased longevity and constitutes an important burden 
on healthcare spending.2–4  
 
Recent years have seen several dramatic advances in the treatment of IA in general, and 
particularly in RA. The patterns of clinical response are remarkably similar for agents with 
different targets challenging our understanding of disease mechanisms. While it is true that 
the last two decades have witnessed an unprecedented, if qualified, success in treating RA, a 
substantial portion of patients still do not achieve low disease activity or remission.5,6 
 
The main challenges in biomedicine and translational research in RA focus on early diagnosis, 
personalised medicine, and the development of meaningful outcome assessments.7 It is 
logical to hypothesise that each of these aims can be facilitated by the identification and 
development of appropriate biomarkers. However, while peripheral blood biomarkers such 
as rheumatoid factor and anti-citrullinated peptide antibodies (ACPA) have been shown to be 
relatively specific and may predict development of RA in asymptomatic individuals,8,9 they 
may only be found in 70-80% of RA subjects. Indeed, beyond these factors our repertoire of 
blood biomarkers to assist with diagnosis, disease progression and response to therapy is 
currently extremely limited.10,11 
 
Since the synovium is the principal target of inflammation in RA, and the specific resident 
fiblroblast-like synoviocyte (FLS) is implicated in the pathogenesis of synovitis, one promising 
approach in the search for biomarkers may be the detailed analysis of the inflamed synovial 
tissue. Using a combination of established methodologies, together with incorporating new 
high-throughput technologies with the capability of detailed examination of genes and their 
products on a scale never before possible, a new opportunity awaits in the search for these 
biomarkers. 
 
 
1.2 Anatomy and Physiological Regulation of the Synovial Joint 
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The synovial joint comprises opposing bones, with the articular surface covered by cartilage. 
The main protein in bone is type I collagen, while cartilage, which is found on the articulating 
surfaces, comprises mainly type II collagen and proteoglycan molecules. The non-articulating 
surfaces are lined by a thin adventitious layer known as synovium. Normal synovial tissue 
comprises 1 to 3 layers of specialized columnar FLS interspersed with macrophages.12 The 
entire structure is housed by a fibrous capsule, and together with ligaments, muscles and 
tendons, this confers strength and stability to the joint. 
 
Several factors contribute to the maintenance of normal homeostasis in the synovial joint. 
These include normal expression of the protective lubricin13, FLS secretion of matrix 
metalloproteinases (MMPs), immune sentinel roles played by resident macrophages and FLS, 
the regulated entry and exit of leukocytes involved in immune surveillance, and local 
regulation by cytokines and growth factors. 
 
Cytokines and growth factors are important regulators of FLS and chondrocytes.14–16 
Cytokines are categorized either as pro- or anti-inflammatory depending on their immediate 
effect on specific tissue, although there is considerable potential for pleiotropism depending 
on the cells targeted and the microenvironment. These regulators are ubiquitous in the 
synovium and synovial space and make their way either by filtration from plasma, or secretion 
by FLS, chondrocytes and the surrounding tissues.16  
 
The joint is a dynamic environment that is subject to minor trauma continually, through 
movement, and in some joints, compression due to weight bearing, and is therefore subject 
to continued wound healing and repair processes. It is therefore necessary for articular 
cartilage and adjacent bone to be continually remodelled in a cycle of synthesis and 
degradation. This requires a balance of anabolic and catabolic enzyme activity in both 
cartilage and bone. 
 
Carefully regulated proteolytic enzymes are responsible for the balance between anabolic 
and catabolic processes within the joint and cartilage.17 Matrix degrading enzymes such as 
MMPs are present in normal synovial fluid, but are higher in concentration in RA, psoriatic 
arthritis (PsA) and osteoarthritis (OA).17–19 The collagenases (MMP-1,-3, -8,-13 and -18) are 
the most important of these enzymes as they are the only known enzymes that can directly 
cleave collagen at neutral pH,20 but other MMPs continue this breakdown when the triple 
helix collagen structure has become unravelled.21 
 
Serine and cysteine proteinases are required to activate pro-MMPs (to MMPs) after they are 
secreted. Furthermore, inhibitors of these proteinases (e.g. tissue inhibitors of 
metalloproteinases (TIMPs), and inhibitors of serine proteinases (SERPINs)) are also present 
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in the normal joint. The levels and activity of these enzymes can be monitored indirectly by 
measuring their degradation products in the synovial fluid.22 
 
 
1.3 The Inflamed Joint 
 
The inflamed synovium has been studied at several levels: macroscopic, microscopic and 
molecular. Synovium is the primary target of disturbed immunomodulatory pathways in RA. 
Rheumatoid synovial tissue appears macroscopically hyperplastic and hypervascular (Figure 
1A-B), while microscopically there is intimal lining layer hyperplasia and accumulation of 
inflammatory cells including T and B lymphocytes, plasma cells, macrophages, neutrophils, 
mast cells, natural killer and dendritic cells in the synovial sublining (Figure 1C-D).23 Like the 
target organ in other autoimmune diseases (e.g. Sjogren’s syndrome, autoimmune 
thyroiditis) infiltrating T and B cells have been demonstrated to form aggregates with varying 
degrees of organisation, and the potential to produce disease specific ACPA.24,25 
Angiogenesis accompanies this cell accumulation, but it occurs in an abnormal manner 
resulting in different patterns of blood vessels associated with particular types of 
inflammatory arthropathies.26 Additionally, the new blood vessels appear to be in an 
immature state.27 The new vessels allow for increased leucocyte migration and the synovial 
tissue transforms into an invading ‘pannus’, that may cause cartilage and bone 
destruction.28,29 Despite increased vascular supply, profound hypoxia in inflamed synovial 
membrane in vivo has been demonstrated.30 
Many of the pathological changes manifest in the inflamed synovial tissue are observable in 
the synovial fluid (SF), which has also been studied intensively. Inflammation alters the 
permeability of synovial tissue.31 In relation to RA synovium, the permeability to large 
molecules is increased, but that of small molecules is decreased (e.g urea and glucose). This 
is due to a combination of increased permeability of the vessels, cellular infiltration and 
synovial hyperplasia. The total protein content in SF is higher in inflammation and synovial 
inflammation inhibits the ability of the synovium to selectively filter proteins from entering 
and leaving the joint space.  
The molecular weight distribution of the lubrication macromolecule hyaluronic acid (HA) is 
also altered, with a shift towards lower molecular weight forms in RA.32 There is increased 
loss of HA from the joint and the mean HA concentration is lower in OA and RA synovial 
fluid.33,34  
Pathological SF samples have markedly raised cytokine concentrations.35 The role of cytokines 
in initiating and perpetuating the synovial inflammatory response continues to be studied 
intensively and has already lead to the development of several useful therapeutic agents, and 
the identification of further potential targets.16 Changes in the cellular infiltrate of RA synovial 
tissue were recognised from an early stage to be associated with the clinical course of disease 
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and were used to identify specific responses to conventional and biologic disease modifying 
anti-rheumatic therapy.36–38 
 
Synovial biopsy 
2.2 Retrieving Synovial Tissue Samples 
The utility of synovial biopsy has been demonstrated in increasing our understanding of the 
pathogenesis of RA, in identifying potential therapeutic targets and evaluating current and 
new treatments.36–58It has also been proposed that synovial biopsies may give insight into the 
mechanism of action of a given agent.59  
Synovial tissue may be obtained by needle biopsy, arthroplasty surgery, arthroscopically, or 
using ultrasound to guide the biopsy needle or grasping forceps (Figure 2).59 Arthroscopic 
biopsy allows direct visualisation of the synovium and the operator can select an area of 
synovium to biopsy. Ultrasound depicts synovial thickness in greyscale and synovial 
vascularity with Doppler to assist in selecting a suitable biopsy site. While blind biopsy has 
been validated, arthroscopic and ultrasound guided biopsy are favoured by the majority of 
investigators for proof of concept experiments, as sampling is more specific for synovial tissue 
rather than connective tissue.53 
Arthroscopic and ultrasound guided biopsy are safe and well tolerated. Data from 15,682 
arthroscopies performed by rheumatologists revealed a complication rate for haemarthrosis 
of 0.9%, for deep vein thrombosis of 0.2%, and wound and joint infection both of 0.1%.60 This 
incidence is reproducible at other centres where the overall complication rate was shown to 
be less than 0.3%.Similarly, an overall major complication rate is reported as 0.4% for 
ultrasound guided biopsy procedures.61 
One study of biopsies in RA patients taken from both an inflamed knee joint and a small joint, 
showed similar mean cell numbers for all markers investigated in the synovial sublining in both 
sample sources.62 Of further note, patients with clinically evident disease manifest at small joints have 
been shown to have similar abnormalities in clinically uninvolved knee joints, albeit at lower 
expression levels.62-64 However, intimal lining layer hyperplasia appeared to depend on local 
processes ; there was no correlation of the numbers of intimal macrophages or FLS between the 
different joints. Consistent with these findings, there are differences in DNA methylation and 
transcriptome signatures in FLS from different joints of RA patients as well as differences in FLS 
invasiveness depending on their positional memory. 65, 66 Questions remain about where to biopsy 
within a given joint. In particular there have been concerns that mediators of inflammation 
may be differentially expressed in different parts of the same joint, especially between the 
cartilage pannus junction (CPJ) and non-CPJ sites which are known to behave differently. 
However for T-cells67,68, plasma cells68, several MMPs68 and granzymes68, there have been 
similar results for biopsies from CPJ and non-CPJ sources. One study did find a difference for 
7 
 
macrophages63, but others did not.67,68 Studies examining the number of synovial tissue 
specimens for reproducible research studies suggest at least six biopsy specimens is the 
optimal number.59, 70 
Although synovial tissue analysis plays a minor clinical role in the differential diagnosis of 
arthritis (e.g. infectious, granulomatous, infiltrative diseases or crystal arthropathies), there 
are still profound unmet needs regarding predictors for diagnosis, disease progression and 
response to treatment. Therefore, studies of synovium have recently expanded beyond 
immunohistochemistry to involve methods of tissue digestion, homogenisation and indeed, 
whole tissue culture. The methods of examining synovial tissue at a molecular level include 
detailed ‘omic’ technology discussed in greater detail below. To this end the synovial tissue 
obtained from the joint is placed on saline-dampened gauze, snap-frozen in OCT or placed 
directly into RNAlater. The synovial fluid is centrifuged and a cell pellet may be isolated or 
separated, using Ficoll gradient, will provide synovial fluid mononuclear cells.Synovial fluid 
may reflect the synovial compartment better than blood but still provides only indirect 
information therefore studies of the synovium, the target tissue of RA is essential.71 
Various prognostic biomarkers for RA have been identified in SF and validated in serum.72 
Studies performed using this strategy first identified proteins that may be of interest in the 
synovial fluid, and then searched for antibodies to these proteins in the plasma.73It is possible 
that this methodology may be useful in future experiments of synovial tissue, and the results 
of such research may be more easily translated into clinical practice. 
Since 2002, cohorts of patients with early arthritis have been gathered. Having a cohort of 
early arthritis patients with clinical data, histological data, DNA and mRNA arrays plus 
proteomics is an instrumental resource for investigating differences in synovial tissue, 
comparing several inflammatory joint diseases with persistent self-limiting, persistent active 
disease as well as erosive and non-erosive disease.74 
Most research with synovial biopsies has been performed from RA patients but some results 
suggest that synovial tissue sampling may be used in other inflammatory arthropathies such 
as psoriatic arthritis.71, 75-77 This research aims to gain a fuller understanding of disease 
pathogenesis, mechanisms of action of current treatments, and the identification of novel 
targets and biomarkers. Indeed, the effects of various treatments for RA on the synovium has 
been studied, and the principal results of these data are presented in table 1. 
 
2.2 Pathogenesis of Synovitis 
 
Synovial tissue inflammation is preceded by activation and proliferation of endothelial cells 
that form new blood vessels (angiogenesis) as one of the earliest changes. The newly 
activated vessels are the gateway for leukocyte infiltration into the synovium, actively 
recruiting immune cells into the tissue. This results in an expanding synovial pannus 
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characterised, in RA, by hyperplasia of the intimal lining layer and often invasion of pannus 
cells into the nearby bone producing erosions. Therefore, the synovium is the target tissue in 
RA and if studies are confined to examining cellular and molecular alterations in the 
peripheral blood then important information may be completely ignored. For example, Th17 
cells are expanded in the blood of some RA patients, this lead to clinical trials of anti-IL17 
monoclonal antibodies, however as limited Th17 expansion occurs within the synovium, this 
therapeutic approach achieved little effect78. Indeed, studies have shown enrichment of ex-
TH17 cells at the site of inflammation in SF and ST from patients with RA79. Additionally, the 
primary invasive cells in RA are the FLS but these have not yet been associated with a 
circulating biomarker80. 
 
2.3 Early Arthritis and Early Diagnosis 
 
Some progress has been made in earlier diagnosis of RA , however signs of joint destruction 
may already be present at the time of diagnosis.81 We know today that early, aggressive 
treatment is more successful than delayed treatment.82, 83 Therefore the utility of biomarkers 
in securing a diagnosis as early as possible will allow treatment in the most timely manner, 
securing the best outcomes.84 Those with undifferentiated arthritis may benefit most from 
this. Although ACPA are reasonably specific (96%), the diagnostic sensitivity in early arthritis 
is 57%.82  Up to 30% of RA patients never develop ACPA.85 An association has been defined 
between the presence of circulating ACPA and subsequent development of RA in subjects 
with arthralgia,87 and with bone erosions in early untreated subjects.88 Delay in diagnosis of 
RA may arise from either a lack of a definitive biomarker, or a failure to meet current 
diagnostic criteria, and these criteria have a significant reliance on biomarkers. Therefore, 
despite the advent of ACPA, there remains a need to identify further and specific susceptibility 
biomarkers. Recently, biomarkers for RA in those without detectable circulating ACPA have 
been identified, and this RA subset represent an important group to study, and may 
contribute greatly to our understanding of the disease pathogenesis.89, 90  
The so-called ‘at-risk of arthritis’ cohorts have been the subject of much research in recent 
years. One potential corollary of this is the promise of cure and prevention of RA, where the 
initial break in self-tolerance is identified and targeted therapeutically.91  
A positive ACPA status in those with arthralgia is associated with the subsequent development 
of arthritis in only about 20-30% of these people after 30 months of follow up.92, 93 The 
synovial tissue of patients who are at risk of arthritis has also been examined in two relatively 
small studies Little evidence of synovitis was found in the first and subtle T-cell infiltration 
was noted in the second.94 Data on alternative tissues such as lung and lymph node that may 
be important in the very early stages of arthritis as sites of first antigen presentation.94, 95  
It is suggested that a ‘window of opportunity’ may exist during which RA can be most 
successfully treated. In initial studies few molecular differences had been observed in the 
9 
 
synovium comparing early and late disease.23, 96  Recently, a highly expanded, specific T-cell 
clone has been identified in early RA, which underlines the importance of T-cells in early stage 
disease.97 Epigenetic changes in FLS over time may define the different stages of RA after 
clinical onset of the disease.   
In recent preliminary reports of ultrasound guided biopsies in unselected treatment-naïve, 
early arthritis patients compared to established RA, there was increased tissue expression of 
macrophage derived chemokines - CXCL4 and CXCL7 in RA only during the first 3 month 
window of symptom duration, and not later in disease.98 
Synovial biopsy may be useful, as a diagnostic and prognostic tool, for the differential 
diagnosis in early inflammatory arthritis in whom synovial CD22 and CD38 expression may 
distinguish between RA and non-RA disease.99 The value of synovial biopsy markers as 
selected diagnostic and prognostic markers to establish an early diagnosis is clearly still 
evolving. 
A recent study included 50 patients with early arthritis, who had undergone synovial biopsy 
at inclusion and were followed for two years.100 The focus was on the angiogenic processes 
in the initiation and perpetuation of synovial inflammation, in particular vascular endothelial 
growth factor (VEGF) and angiopoietins 1 and 2 (Ang-1 and Ang-2) and their tyrosine kinase 
receptors VEGFR and TIE-2. Expression of TIE-2 was significantly increased in the group with 
erosive disease as compared to the group with a self-limiting disease, and plasma–TIE-2 was 
significantly increased in the groups with persistent non-erosive disease and persistent 
erosive disease as compared to the group with self-limiting disease. Similarly, JNK activation 
is elevated in RA patients compared to undifferentiated arthritis, before classification criteria 
are met.101 
Although more research is needed, these studies suggest that a synovial biopsy at disease 
presentation could be a useful tool for both patients and physicians, for early disease 
stratification into short self-limiting course versus severe persistent inflammatory course, and 
in the former between erosive versus non erosive disease, thereby informing the most 
appropriate treatment strategy.  
 
2.4 ‘Personalised Medicine’ and Disease Stratification 
 
In addition to diagnostic problems, predicting disease course is imprecise. Identification of a 
subgroup of early arthritis patients who will develop destructive disease may present a 
significant advance in selecting the most effective treatment for an individual patient.102, 103 
This is the so-called ‘tailor-made’ treatment, informed by biomarkers, used to assess what 
has been referred to as ‘disease signatures’.98 A more accurate description of this process is 
disease ‘stratification’.104,105This concept proposes that a disease can be stratified into distinct 
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subsets that exhibit differential outcomes and responses, each subset labelled by a biomarker 
or combination thereof.  
This is important as therapies are commonly selected on a trial and error basis, but less than 
50% of RA patients experience a 50% improvement in their arthritis in response to any single 
biological therapy.106–108 In the time that an ineffective treatment is administered, the disease 
may progress and patients may be potentially exposed to unnecessary adverse events. 
Therefore biomarkers that predict response to a given treatment will be of great clinical 
utility. Synovial biomarkers are likely to be of the greatest clinical utility and a great deal of 
work has concentrated on studying features of inflamed synovium in RA patients with 
samples taken after clinical improvement following treatment. More recently, a number of 
studies have analysed the predictive capabilities of synovial tissue biomarkers for disease 
course and response to therapy. 
 
2.5 Recent advances 
Synovial tissue biopsy procedures and analysis are more widely available throughout the 
world.53 This will inevitably enable a targeted approach to identifying biomarkers in synovial 
tissue. 
With respect to disease stratification, sensitivity and specificity can be theoretically improved 
by combined use of biomarkers. For example a positive clinical response of RA to anti-tumour 
necrosis factor treatment with etanercept has been demonstrated using a biomarker 
signature generated by 13 autoantibodies and 11 cytokines. This study included three 
ethnically distinct populations, and for North Americans it demonstrated a positive predictive 
value of 71%, although independent validation is required.11 
The advent of new proteomic, transcriptomic and genomic technologies, and the ability to 
combine clinical and radiological markers with these technologies, should make stratifying 
disease the norm in the future. It is possible that disease stratification will become so sub-
categorised such that it is truly approaching personalised medicine. The ‘omics’ approach has 
been usefully applied to identify key players and protein interactions in several diseases. 
Studying the genome, the RNA or the protein will each have different sets of bias and 
variance, and it has been argued that combined approaches may lead to a more accurate 
assessment of important protagonists.104 
Proteomics offers the advantage that the functional units of the cell are being studied directly, 
likely most accurately representing what is actually happening in the synovium. The 
development of technologies such as SomaLogics that have the power to measure thousands 
of proteins in small tissue volumes has the potential to allow a more complete 
characterisation of the disease network of RA. In RA the proteomics approach has so far 
focussed on peripheral blood mononuclear cells, serum and synovial fluid72,73,109,; the 
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possibility that the synovial tissue itself may hold the key to unlocking the disease network 
has yet to be fully exploited. Furthermore, new technologies in protein separation, processing 
and identification are expected to increase proteome coverage. 
In relation to transcriptomic analysis, microarray technology has been, to date, the most 
frequently employed strategy in the field of biomarker research. This facilitates the 
identification of candidate genes in pathophysiological processes. However, gene expression 
levels do not always predict protein levels, due to transcriptional and translational regulatory 
mechanisms and the activity of protein degradation processes.17 A good example of the use 
of transcriptomic data was demonstrated while determining a rule-based classification that 
allows differentiation between RA and osteoarthritis.110 
Microarrays contain probes for thousands of different genes that makes them suitable for 
screening large cohorts. The high throughput techniques used in transcriptomics, however, 
also allow detection of significant gene expression differences with modestly sized cohorts.111 
Transcriptomic analysis is already being used to examine the gene signature of synovial tissue, 
augmented by the newer sequencing technologies that permit deeper transcriptional 
coverage than microarrays, including spliced variants. 
There have been a number of studies where DNA array technology used to study gene 
expression in RA has been shown to be a useful and practical methodology. Different subtypes 
of RA patient synovia have also been characterised by gene expression analysis.112,113 Gene-
expression variance among RA patients has been described impacting several pathways 
involved in cell proliferation, cell survival, angiogenesis and regulation of inflammation.114  
 
Biomarkers 
 
3.1 General Considerations 
 
 
3.2 Cellular Composition 
 
Simple cell count densities (or cellular infiltration) were appreciated as synovial tissue 
biomarkers associated with RA, more than 20 years ago. In a study published in 1989, a group 
showed that there was a decrease in T cell numbers after at least 6 months of gold treatment. 
They also reported a reduction in the ratio of T-helper cells to T-suppressor/cytotoxic cells in 
those who were treated successfully. Macrophages were not reported in this study. 
Furthermore, the number of biopsy samples where B cells could be identified decreased from 
36% before successful treatment to 7% after treatment.36 
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The most convincing evidence for a cellular biomarker of treatment response points to the 
use of CD68 macrophages.  Patients taking prednisolone had a reduction in synovial 
macrophages, expressing cell surface CD68, after two weeks of treatment compared with 
controls. The reduction in CD68 staining cells was mostly attributable to a decrease in the 
number of macrophages localising to the synovial sublining. There was also a decrease in the 
CD4 and CD5 (T and B cells) and CD38 (plasma cells) and CD55 (fibroblast-like synoviocyte 
(FLS)) cells.42 
In an earlier study a reduction in synovial macrophages was observed 12 weeks after gold 
therapy. CD68 cells were most commonly identified in all layers independently of the site of 
synovial biopsy. No significant change in lymphocyte numbers was noted following 
treatment.115  
A significant reduction in macrophages in the synovial sublining region following treatment 
with disease-modifying antirheumatic drugs (DMARDs), mostly methotrexate and gold, was 
demonstrated in another study.116 This was particularly pronounced in those who were 
responding clinically by ACR criteria. Although a significant reduction in memory T cells was 
observed, (and this was interestingly associated with CRP reduction), memory T-cells could 
still be found in the synovium of patients who attained remission.  
Synovial macrophages were also significantly reduced in the sublining after 16 weeks of 
treatment with leflunomide, and in the intimal lining layer after 16 weeks of methotrexate 
monotherapy. Synovial T cell numbers were decreased with both treatments but did not 
reach statistical significance in this study.41 Whilein a similar study, after 16 weeks of 
methotrexate, a decrease in synovial CD3, CD8, CD38, CD68 and Ki67 were demonstrated to 
be statistically significant. Notably CD4 infiltration was not reduced in this study.117 
Treatment with infliximab has been shown to reduce CD3 (T cell) in repeat synovial biopsies 
taken 4 weeks after treatment, and this finding was associated with clinical response.39  In ten 
patients with longstanding RA who received infliximab, reduced numbers of synovial CD3 (T 
cells), CD22 (B cells) and CD68 macrophages, 2 weeks after treatment were demonstrated in 
a separate study.45 In a study of infliximab versus placebo in which 24 patients with active RA 
underwent arthroscopy and biopsy before, and 48 hours after infliximab, revealed a 
significant reduction in CD68 intimal macrophages, as well as a non-statistically significant 
reduction in CD68 macrophages, T cells and plasma cells in the sublining. In a large 
prospective study in 143 RA patients the clinical response to infliximab was predicted by the 
number of TNF producing cells, CD68 macrophage subsets and synovial expression of TNF.118 
In a follow-up study, the number of lymphocyte aggregates was also predictive of the clinical 
response.119 Positivity for lymphocyte aggregates increased the power to predict the clinical 
response, when analyzed in a prediction model that included baseline disease activity 
evaluated by the Disease Activity Score in 28 joints, ACPA positivity, and synovial TNF 
expression. 
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Anakinra, a specific Il-1 antagonist, has also been shown to significantly reduce the synovial 
intimal macrophage population.43 A significant decrease of intimal lining CD68 macrophages 
was observed following rituximab infusion in responders.54  
Synovial response to rituximab has also been assessed by serial biopsy. A series of 6 patients 
with seropositive RA who had synovial biopsy before treatment with rituximab, and then 4 
were re-biopsied after 8 weeks has been reported. The authors assert that although it is 
known that rituximab depletes circulating B cells, as well as B cells in salivary glands, little is 
known of its effect on synovial tissue. 4/6 agreed to follow up biopsy. 2 had complete 
depletion of CD20, 1 had no change and 1 biopsy was insufficient to analyse.120 
In other studies rituximab induced a similar variable depletion in synovial B cells with an 
indirect decrease in macrophages, T cells and plasma cells at the time of the clinical 
response.121,122 Of interest, the change in plasma cells was associated with the clinical 
response.  
The utility of CD68+ macrophages in the sublining layer as a candidate biomarker was systematically 
tested across different interventions and kinetics.123  It was shown that changes in numbers of synovial 
sublining CD68+ macrophages correlate with clinical improvement independently of the therapeutic 
strategy. A study designed to determine if the correlation between the change in number of synovial 
sublining CD68 cells and change in DAS28 was confirmed in a multicentre study with excellent  inter-
centre agreement.124 The number of CD68 macrophages decreases with a reduction in disease 
activity as measured by the DAS, thus demonstrating that CD68 numbers could be used as a 
biomarker of therapeutic response.123 
Furthermore, synovial CD68 expression is superior to clinical evaluation as it is less susceptible 
to both the placebo effect and expectation bias (59% of delegates at OMERACT agreed)123, 125. 
It could therefore be used to assess the therapeutic efficacy of novel treatments.124 In 
conclusion, synovial macrophage CD68 expression as a synovial biomarker demonstrates 
validity, reliability and feasibility is as a biomarker of disease activity and response to 
treatment both in early and established RA. 
A number of studies addressed whether markers of synovitis are associated with clinical 
phenotype or development of a persistent, erosive disease course. In two large studies in 
established RA, large lymphocyte aggregates were found in around 30% of patients but did 
not associate with a clinical phenotype.126,127 In early arthritis, the presence of lymphocyte 
aggregates did not predict an aggressive disease course and aggregates were rapidly 
diminished by several anti-rheumatic treatments.119,128 Taken together, these studies suggest 
that lymphocyte aggregates are a pro-inflammatory phenomenon and not a persistent 
primary driver of synovitis. In contrast, as described above, biomarkers of angiogenesis, 
namely the activation of the tyrosine kinase receptor TIE-2, as well as increased JNK 
expression predicted an aggressive disease course in early arthritis patients.101 
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3.3 Cytokines 
The increased expression of several cytokines in the inflamed synovial tissue is well 
established, and for TNF and IL-6 concentrations correlation with disease activity, 
independent of disease duration, has been demonstrated.27 The levels of CCL2/MCP-1 were 
also found to be increased in RA serum and synovial tissue.50 
With regards to treatment effect, the expression of IL-1ß and TNF was 40% (95% CI 18–56%) 
and 52% (95% CI 10–74%) respectively lower following prednisolone therapy compared with 
placebo. Notably, this effect was mainly attributable to changes in the synovial sublining, and 
appeared to correlate with clinical improvement.42 Significant cytokine expression changes 
after 12 weeks of gold treatment, in three areas of synovium; lining, perivascular and 
connective tissue, have also been reported. In the intimal lining layer, IL-1α, IL-1ß and IL-6 
levels were statistically significantly reduced after treatment, and this seemed to correlate 
with clinical response. TNF was also reduced in all three areas, but did not reach statistical 
significance in the lining.  
TNF was only slightly reduced in synovial samples after 16 weeks treatment with either 
methotrexate or leflunomide. IL-1ß was only moderately reduced in the leflunomide-treated 
patients while reductions in the methotrexate patients were significant, which highlights 
potential different mechanism of action between DMARDs.41 In a separate study IL-1ß, but 
not IL-1α was shown to have a statistically significant reduction in expression after 16 weeks 
of treatment with methotrexate, and this again seemed to correlate with clinical response.117 
In biopsy samples of ten active RA patients taken 2 weeks after infliximab, IL-8 and MCP-1 
were shown to be reduced in both the lining and sublining, and, despite a downward trend in 
synovial expression of Gro α, RANTES, and MIP-1b this was not significant.45 
Acute serum amyloid A (A-SAA) expression and production has been demonstrated in RA 
synovial tissue and A-SAA induces angiogenesis, cell matrix interactions,  chemokine and 
MMP expression in RA.130 A–SAA has a significant role in the inflamed joint increasing 
expression of MMP-1, MMP-3, MMP-13, and MMP/TIMP expression in RA FLS and synovial 
explants. Furthermore, blockade of its receptor (scavenger receptor class B type 1 (SR-B1)) 
and TLR2 inhibited migration and invasive mechanisms. Importantly, A-SAA has the ability to 
induce TNF expression in RA synovial explant cultures, while baseline serum A-SAA levels 
correlated with the 28-joint swollen joint count and 1-year radiographic progression 
independently. Therefore, A-SAA is a promising biomarker of disease activity both in the 
synovium and in the serum.131  
 
3.4 Chemokines 
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Leucocytes are attracted to the target tissue by soluble chemotactic cytokines termed 
chemokines, released from activated cells in the tissue to stimulate leucocyte migration 
through the endothelial barrier.132 The chemokines IL8/CXCL8 and MCP-1/CCL2, among 
others, are expressed abundantly in RA synovial tissue. Previous work has shown that the 
development of clinical signs of RA synovial inflammation is specifically associated with 
increased synthesis of the CXCL8133 and expression in synovial tissue reflects response to 
therapy in RA patients. In addition, a proof of concept study of an oral CCR1 antagonist in RA 
patients showed significant reduction in synovial macrophages and chemokine expression.134 
 
 
3.5 Growth Factors/Adhesion Molecules 
 
ICAM-1 expression was significantly reduced in patients treated with both leflunomide and 
methotrexate. Notably, a decrease in ICAM-1 was seen in those that responded to 
leflunomide and to methotrexate, while non-responders did not experience a statistically 
significant decrease. VCAM-1 was reduced in both groups, but this difference was significant 
only in the leflunomide-treated patients.41 
Another study demonstrated that VCAM-1 and E-selectin were both statistically significantly 
reduced in expression after 16 weeks of treatment with methotrexate, but in this study ICAM-
1 did not reach statistical significance.117 Treatment with infliximab has been shown to reduce 
VCAM-1 and E-selectin in repeat biopsies taken 4 weeks after treatment.39 
In relation to treatment with anakinra, a patient taking the dose of 150mg/day, was shown to 
have a 74% reduction in synovial membrane E-selectin, but the 5 patients taking the lower 
dose (30mg/day) did not demonstrate this. No change was seen in P-selectin. A significant 
decrease in ICAM-1 and VCAM-1 was seen in the high dose patients, and a small decrease in 
2 of the 5 on the lower dose of anakinara.43 
 
3.5 Mediators and Products of Bone, Cartilage and Tissue 
Degradation 
 
Type II collagen is the main collagen of articular cartilage, and is excessively degraded in RA. 
It is known that collagen biomarker and MMP levels predict radiographic progression of RA, 
and therefore may act as a prognostic biomarker.135, 136 A study with the primary objective of 
attempting to understand more about the mechanism of action of methotrexate (19 subjects) 
and leflunomide (16 subjects) demonstrated that MMP-1 was significantly reduced by both. 
The level of TIMP-1 was significantly reduced in the leflunomide-treated patients, but not the 
methotrexate-treated patients. Furthermore, both drugs reduced the overall expression of 
MMP-1 and the MMP-1: TIMP-1 ratio after 4 months of treatment. The changes were more 
pronounced in patients who fulfilled the ACR 20% response criteria.41 
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A number of studies analyzed the effect of immunomodulatory treatment on synovial 
mediators of bone destruction. Treatment with both infliximab and etanercept increased the 
expression of osteoprotegerin (OPG) in synovial tissue and had no effect on RANKL, resulting 
in an increased OPG:RANKL ratio.49 In contrast, rituximab induced a 99% decrease in receptor 
activator of nuclear factor κB (RANK)-positive osteoclast precursors and a decrease of 37% in 
RANKL and a trend towards reduced synovial OPG expression. In serum, both OPG and RANKL 
levels were significantly reduced, but the OPG/RANKL ratio increased (157%).137 Finally, 
abatacept did not exert a significant effect on synovial OPG, RANK or RANKL mRNA expression 
in a study in 16 patients.138 
The family of S100 proteins are a closely related group of low-molecular weight (9–14 kDa) 
acidic calcium-binding proteins. Originally described in oesophageal epithelium, as well as 
neutrophils and macrophages, they are involved in calcium dependent cell activities such as 
cytoskeleton regulation and cell migration and adhesion. The extracellular role of these 
proteins is of interest as they have been found to be overexpressed in inflammatory 
compartments. They are in effect pro-inflammatory cytokines. S100A12 has important 
activities in relation to innate and acquired immune responses.139 One study using 
quantitative proteomics demonstrated an association  between the severity of joint erosion 
in RA and the S100 proteins A8, A9 and A12 levels.109 The S100 proteins myeloid-related 
protein (MRP)-8 and MRP-14 regulate myeloid cell function and control inflammation. Before 
initiation of treatment, responders to targeted treatments showed significantly higher 
MRP8/14 protein complex levels compared with non-responders. Moreover, in responders to 
adalimumab, infliximab or rituximab treatment, MRP8/14 levels decreased after 4 weeks of 
treatment, but not non-responders.140 
 
3.6 Antigens and Antibodies 
Expression of antigenic proteins has been described in RA synovial tissue. The presence of 
deiminated proteins, such as the α- and β-chains of fibrin, in RA synovium appeared to be 
major antigenic targets of ACPAs.141 In addition, anti-Sa antibodies that recognize deiminated 
vimentin appear to be specific for RA and have been isolated from RA synovium.142 Finally, 
intracellular citrullinated proteins colocalizing with ACPA reactivity have been demonstrated 
in RA synovium.143 but the presence of citrullinated antigens is not specific for RA synovial 
tissue.144 It has also been shown that anti-fillagrin antibodies are produced by local plasma 
cells resident in the RA pannus.145  
 
3.7 Genes and Transcripts 
 
In a study in 18 RA patients treated with infliximab several biological processes, related to 
inflammation, were up-regulated in pre-treatment synovial tissue biopsies in patients who 
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responded to therapy.146 In a larger follow-up study, Lindberg et al reported the results of 
RNA analysis of synovial biopsies of 62 patients with RA before treatment with infliximab. 
They found that the presence of lymphocyte aggregates dominated the expression profiles 
and that there was a significant overrepresentation of lymphocyte aggregates in patients who 
had a good response, which confounded the analysis. Nonetheless, in those that were 
lymphocyte aggregate positive, 38 transcripts were associated with differences between 
good and non-responders.147  
In a study of paired synovial biopsies of RA patients, before and 12 weeks after adalimumab, 
genes were differentially expressed between biopsies of responders and non-responders. 
These genes could be split into two distinct families: genes involved in the regulation of 
immune responses and genes involved in the regulation of cell division. To confirm the 
microarray findings, synovial expression of selected molecules was assessed using specific 
antibodies. Synovial expression of IL-7R, CXCL11, IL-18, IL-18rap, and MKI67  was significantly 
higher in poor as compared with moderate and good responders, thereby serving as a 
potential biomarker of response to adalimumab.148 
In another study of paired synovial biopsies of RA patients before and after rituximab 
treatment clinical responders demonstrated higher expression of macrophage and T cell 
genes, while clinical poor responders showed higher expression of interferon-α and 
remodelling genes.149  
 
3.8 Other 
 
The properties of the cells in the inflamed synovium differ markedly from normal cells 
Profound hypoxia in the inflamed synovial membrane has been described in vivo.30 Low tissue 
partial oxygen pressure (tPO2) levels in the inflamed synovial joint tissue are significantly 
associated with increased markers of macroscopic and microscopic inflammation. There is an 
association of tPO2 with macroscopic synovitis as well as CD68 and CD3 cell infiltrate in the 
sublining, and various pro-inflammatory cytokines (TNFα, IL1β, IFNγ and the chemokine 
MIP3α). When primary synovial fluid cells were exposed in vitro to pO2 levels, similar to those 
in the inflamed joint, there was a significant increase in cell migration.150 
 
 
 
Conclusion and Current Limitations 
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Much of the work on serial synovial biopsies has been performed on patients with known 
diagnoses, and has been performed to investigate responses to treatment. There remains a 
critical need for identifying biomarkers for diagnosis which can be applied in clinical practice.  
Biomarkers may reduce the time taken and the number of patients required to screen for the 
potential efficacy of new drugs.52,151 The number of patients with active disease eligible to 
participate in studies is limited. As with all trials, the number of patients who are to be put at 
risk by exposure to drugs at an early stage of development, as well as to be placed on placebo, 
are restricted by ethical considerations.152  
 
Although finding biomarkers in peripheral blood is attractive because it is more feasible and 
less invasive than synovial biopsy, since inflamed synovium is the ultimate target of 
inflammation, it should be a potentially rich source of potential biomarkers. Furthermore, 
many confounding factors might interfere with peripheral blood profiles. Some authorities 
have suggested that a more targeted approach to searching for serum markers should be to 
first identify potential biomarkers in the inflamed synovial joint, and later studying the plasma 
for the presence of the same biomarker.140 Such an approach in RA patients has demonstrated 
clinical utility when candidate peripheral biomarkers of synovial pathotype predicted 
response to biologic therapy.153  
Although new technology has enabled faster and more complete analyses of proteins, 
because of the high complexity in protein and protein isoforms in the synovial joint, 
interpreting the results of ‘shotgun’ proteomics is a challenging endeavour.  
New technologies are experiencing difficulties. Expression levels from three widely used 
microarray platforms demonstrated poor reproducibility.154 In addition, as there are high 
levels of background signals in array datasets, there is a decreased sensitivity to transcripts 
present in low numbers.155 
The development of high quality immunoanalytical assays can be slow and expensive. This 
makes the verification of candidate biomarkers a challenging process, and at the moment, 
despite the increase in availability of means to biopsy synovial tissue, there remains a lack of 
diagnostic makers.  
While there are a great many genomic biomarkers that can predict response to treatment, or 
those at most risk of adverse events in many areas of medicine, rheumatology appears to 
have experienced only limited benefit from this emerging field. Many studies have attempted 
to identify biomarkers to predict response to anti-TNF treatment, but to our knowledge, only 
those reported above have used synovial tissue to search for these.119,147,148 
In addition, where data from control synovial tissue specimens is available, osteoarthritis is 
often used as a disease control, although it is increasingly recognised that osteoarthritis has 
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an underlying inflammatory response, albeit significantly limited and less associated with 
specific autoimmunity than RA.   
It is likely that in the near future a reasonable goal will be to stratify disease before the 
phenotype is established, and this represents an early step toward eventual ‘personalised 
medicine’. Identifying surrogate markers is therefore an aim for which synovial tissue is an 
indispensable research tool. 
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